Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - ACELRX PHARMACEUTICALS INC | d435935d8k.htm |
Exhibit 99.1
FOR IMMEDIATE RELEASE
AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
REDWOOD CITY, Calif., November 6, 2012–AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and nine months ended September 30, 2012 and provided a corporate update.
Net loss for the third quarter of 2012 was $8.6 million, or $0.38 per share, compared with a net loss of $5.8 million, or $0.30 per share, for the third quarter of 2011. During the third quarter of 2012, AcelRx recognized revenue of $166,000 resulting from reimbursement for work completed under a research grant from the U.S. Army Medical Research and Materiel Command, or USAMRMC, for development of its ARX-04 product candidate, a single dose Sufentanil NanoTab® for the treatment of moderate-to-severe acute pain.
Research and development expenses for the third quarter totaled $6.9 million, compared with $3.9 million for the quarter ended September 30, 2011. The increase was primarily due to expenditures associated with three ongoing Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, AcelRx’s lead product candidate for the treatment of post-operative pain. General and administrative expenses were $1.4 million for the quarter ended September 30, 2012, compared with $1.9 million for the third quarter of 2011. This decrease resulted primarily from lower intellectual property and market research expenses.
For the nine months ended September 30, 2012, AcelRx reported a net loss of $22.8 million, or $1.09 per share, compared with a net loss of $13.7 million, or $0.83 per share, for the same period in 2011. As of September 30, 2012, AcelRx had cash, cash equivalents and investments of $23.4 million, compared to $31.9 million at June 30, 2012 and $35.8 million at December 31, 2011.
“We continue to make progress in the execution of our Phase 3 program for ARX-01. During the third quarter, we initiated our third Phase 3 clinical trial, received four additional U.S. patents related to our sufentanil NanoTab technology and we were notified that ARX-01 was deemed sufficiently novel that we would be allowed to use the centralized filing procedure for ARX-01 in Europe,” stated Richard King, president and CEO of AcelRx. “In addition, we completed treatment of the final subject in our Phase 3 clinical trial comparing ARX-01 to IV PCA with morphine. We expect to announce top line data from this first trial later this month and results from our two other ARX-01 trials is expected in the first quarter of 2013.”
Review of Third Quarter Accomplishments and Corporate Update
| • | In August 2012, AcelRx initiated the third of three planned Phase 3 clinical trials for ARX-01, a double-blind, placebo-controlled efficacy and safety trial in adult patients with post-operative pain following hip or knee replacement surgery. This study is designed to enroll approximately 400 patients and is being conducted at approximately 45 academic and community hospitals in the U.S. The primary endpoint is the sum of the pain intensity difference to baseline, over the 48 hour study period, or SPID-48, which is the FDA standard for post-operative acute pain studies. |
| • | Dosing of the last patient in the Phase 3 open label, active comparator study comparing efficacy and safety of the Sufentanil NanoTab System to the commonly used IV PCA with morphine is complete, and top line data are expected in November, 2012. Top line results from the two placebo-controlled Phase 3 clinical studies, one treating post-operative pain in patients following abdominal surgery and the other treating post-operative pain in patients following hip or knee replacement, are both expected during the first quarter of 2013. |
| • | During the third quarter, the U.S. Patent and Trademark Office issued four additional patents covering AcelRx’s proprietary NanoTab technology. AcelRx has now received a total of five U.S. patents underpinning its four product development programs and proprietary NanoTab technology. |
| • | The European Medicines Agency, or EMA, notified AcelRx that it will permit registration of the Sufentanil NanoTab PCA System via the centralized procedure. This procedure will allow AcelRx to submit a single Marketing Authorization Application to the EMA for approval to market ARX-01 in all 27 EU member states, as well as in the 4 European Free Trade Association countries. |
| • | In early November 2012, AcelRx dosed the first patient in a Phase 2 study for ARX-04, its single dose sufentanil NanoTab product candidate for the management of acute pain. The study is funded by a grant from the USAMRMC and will enroll approximately 100 patients following bunionectomy surgery, randomizing them into one of three groups to receive one of two sufentanil NanoTab dosage amounts (20 mcg and 30 mcg) or placebo. |
Financial Outlook
AcelRx anticipates that research and development expenses for the fourth quarter of 2012 and the first half of 2013 will increase as AcelRx conducts and completes the Phase 3 clinical trials for ARX-01. Development of ARX-04 through Phase 2 clinical work and Phase 3 preparatory work is expected to be fully funded by a grant from USAMRMC. The development of ARX-04 beyond Phase 2 and initial preparations for Phase 3 is dependent on the identification of additional funding from USAMRMC or other sources. Additionally, AcelRx anticipates modest increases in general and administrative expenses due to costs associated with expansion of its corporate infrastructure to support ongoing development of its product candidates.
Conference Call
AcelRx will conduct a conference call and webcast today, November 6, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results and program updates. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (800) 860-2442 for domestic callers, (866) 605-3852 for Canadian callers, or (412) 858-4600 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company’s website at www.acelrx.com. A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor Relations section of the company’s website at www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx’s lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, is currently in Phase 3 clinical development and is designed to solve problems associated with post-operative intravenous patient-controlled analgesia, including side effects of morphine, invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates that have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain and ARX-03 for mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. AcelRx has initiated a Phase 2 study for a fourth product candidate, ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from the USAMRMC. For additional information about AcelRx’s clinical programs please visit www.acelrx.com.
Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to AcelRx Pharmaceuticals’ financial viability, anticipated increases in research and development and general and administrative expenses, the sufficiency of funds to support its clinical trials and operations, timing of interim and final results of its clinical trials, planned or anticipated future clinical development of AcelRx Pharmaceuticals’ product candidates, including the release ARX-01 top-line clinical trial data, the release and anticipated timing of additional ARX-01 clinical trial data, the anticipated timing for remaining clinical trials, and the therapeutic and commercial potential of AcelRx Pharmaceuticals’ product candidates. These forward-looking statements are based on AcelRx Pharmaceuticals’ current expectations and inherently involve significant risks and uncertainties. AcelRx Pharmaceuticals’ actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: AcelRx ability to raise additional funds to support its clinical trials and operations; the success, cost and timing of AcelRx Pharmaceuticals’ product development activities and clinical trials, including timing, release and implications of interim or final results of the ARX-01 Phase 3 clinical trials; the uncertain clinical development process, including the risk that planned clinical trials may not have an effective design, enroll a sufficient number of patients, or be completed on schedule, if at all; any delays or inability to obtain, regulatory approval of its product candidates; its ability to obtain adequate clinical supplies of the drug and device components of its product candidates; its ability to attract funding partners or collaborators with development, regulatory and commercialization expertise; its ability to obtain sufficient financing to complete development and registration of its product candidates in the United States and Europe; its ability to obtain and maintain regulatory approvals of its product candidates; the market potential for its product candidates; sufficiency of its intellectual property portfolio; the accuracy of AcelRx Pharmaceuticals’ estimates regarding expenses, capital requirements and needs for financing; and other risks detailed in the “Risk Factors” and elsewhere in AcelRx Pharmaceuticals’ U.S. Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the three months ended September 30, 2012. AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.
Contact:
Jim Welch
Chief Financial Officer
650.216.3511
jwelch@acelrx.com
SELECTED FINANCIAL DATA
(in thousands, except per share data)
(unaudited)
| Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
| 2012 | 2011 | 2012 | 2011 | |||||||||||||
| Statement of Comprehensive Loss Data |
||||||||||||||||
| Research grant revenue |
$ | 166 | $ | 408 | $ | 719 | $ | 448 | ||||||||
| Operating expenses: |
||||||||||||||||
| Research and development (1) |
6,948 | 3,947 | 17,113 | 8,922 | ||||||||||||
| General and administrative (1) |
1,410 | 1,866 | 5,290 | 5,086 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
8,358 | 5,813 | 22,403 | 14,008 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss from operations |
(8,192 | ) | (5,405 | ) | (21,684 | ) | (13,560 | ) | ||||||||
| Interest expense |
(573 | ) | (377 | ) | (1,765 | ) | (1,891 | ) | ||||||||
| Interest income and Other income (expense), net |
183 | 21 | 608 | 1,722 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss |
$ | (8,582 | ) | $ | (5,761 | ) | $ | (22,841 | ) | $ | (13,729 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Basic and diluted net loss per common share |
$ | (0.38 | ) | $ | (0.30 | ) | $ | (1.09 | ) | $ | (0.83 | ) | ||||
| Shares used in computing basic and diluted net loss per common share |
22,633 | 19,459 | 20,962 | 16,594 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
|
||||||||||||||||
| (1) Includes the following non-cash, stock-based compensation expense:
|
||||||||||||||||
| Research and development |
$ | 258 | $ | 253 | $ | 762 | $ | 578 | ||||||||
| General and administrative |
304 | 304 | 871 | 768 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total non-cash, stock-based expense |
$ | 562 | $ | 557 | $ | 1,633 | $ | 1,346 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
Selected Balance Sheet Data
| September 30, 2012 |
December 31, 2011 |
|||||||
| Cash, cash equivalents and investments |
$ | 23,375 | $ | 35,785 | ||||
| Total assets |
28,151 | 40,835 | ||||||
| Total liabilities |
28,478 | 23,367 | ||||||
| Total stockholders’ equity (deficit) |
(327 | ) | 17,468 | |||||